Idiopathic subglottic stenosis is associated with activation of the inflammatory IL-17A/IL-23 axis

Objectives/Hypothesis Idiopathic subglottic stenosis (iSGS) is a rare and devastating extrathoracic obstruction involving the lower laryngeal and upper tracheal airway. It arises without known antecedent injury or associated disease process. Persistent mucosal inflammation and a localized fibrotic r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Laryngoscope 2016-11, Vol.126 (11), p.E356-E361
Hauptverfasser: Gelbard, Alexander, Katsantonis, Nicolas-George, Mizuta, Masanobu, Newcomb, Dawn, Rotsinger, Joseph, Rousseau, Bernard, Daniero, James J., Edell, Eric S., Ekbom, Dale C., Kasperbauer, Jan L., Hillel, Alexander T., Yang, Liying, Garrett, C. Gaelyn, Netterville, James L., Wootten, Christopher T., Francis, David O., Stratton, Charles, Jenkins, Kevin, McGregor, Tracy L., Gaddy, Jennifer A., Blackwell, Timothy S., Drake, Wonder P.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objectives/Hypothesis Idiopathic subglottic stenosis (iSGS) is a rare and devastating extrathoracic obstruction involving the lower laryngeal and upper tracheal airway. It arises without known antecedent injury or associated disease process. Persistent mucosal inflammation and a localized fibrotic response are hallmarks of the disease. Despite the initial clinical description of iSGS more than 40 year ago, there have been no substantive investigations into the pathogenesis of this enigmatic and progressive airway obstruction. In these studies, we present the initial characterization of the molecular pathogenesis underlying the fibrosing phenotype of iSGS. Methods Utilizing 20 human iSGS and healthy control specimens, we applied histologic, immunohistochemical, molecular, and immunologic techniques. Results We demonstrate significant activation of the canonical IL‐23/IL‐17A pathway in the tracheal mucosa of iSGS patients, as well as identify γδ T cells as the primary cellular source of IL‐17A. Conclusion Our results suggest that aberrant mucosal immune activation is a component in of the pathogenesis of iSGS. Most critically, our work offers new targets for future therapeutic intervention. Level of Evidence NA Laryngoscope, 126:E356–E361, 2016
ISSN:0023-852X
1531-4995
DOI:10.1002/lary.26098